



UNIVERSITI PUTRA MALAYSIA

***DEVELOPMENT AND STRUCTURE ACTIVITY RELATIONSHIP OF
DIARYLPENTADIENONE AND CHALCONE ANALOGUES AS
POTENTIAL ANTI-INFLAMMATORY AGENT***

SITI MUNIRAH MOHD FAUDZI

IB 2015 42



**DEVELOPMENT AND STRUCTURE ACTIVITY RELATIONSHIP OF
DIARYLPENTADIENONE AND CHALCONE ANALOGUES AS POTENTIAL
ANTI-INFLAMMATORY AGENT**

By

SITI MUNIRAH MOHD FAUDZI

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,
in Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

March 2015

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of University Putra Malaysia.

Copyright © Universiti Putra Malaysia



In the name of Allah, The Most Merciful and the Most Beneficent.

This thesis is especially dedicated to my beloved late mother,

Allahyarhamah Norshimah binti Md Nor,

My parent and parents in law,

Darling husband and precious son.

Without whom none of my task accomplishments would be impossible.

© COPYRIGHT

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

**DEVELOPMENT AND STRUCTURE ACTIVITY RELATIONSHIP OF
DIARYLPENTADIENONE AND CHALCONE ANALOGUES AS
POTENTIAL ANTI-INFLAMMATORY AGENT**

By

SITI MUNIRAH BINTI MOHD FAUDZI

March 2015

Chairman : Associate Professor Faridah Binti Abas, PhD

Institute : Bioscience

The main adverse effects of current non-steroidal anti-inflammatory drugs (NSAIDs), involved the gastrointestinal tract, kidney and blood clotting has lead to the discovery of new drugs with improved safety profile today. Curcumin could be serves as potential NSAID candidate based on its strong anti-inflammatory property and low toxicity. However, its utilization in clinical trials was restricted due to poor pharmacokinetic properties. Thus far, several modifications of curcumin structure have been conducted, and reports have shown that diarylpentanoid scaffold without the β -diketone moiety influenced their anti-inflammatory properties via nitric oxide (NO) production suppression activity and inhibition on pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF- α) and interleukin-6 (IL-6).

In this study, a series of forty-five curcumin like compounds, the 1,5-diphenylpenta-2,4-dien-1-ones and five pyrazoline-diarylpentadienone analogues were synthesized following the Lipinski rule, and evaluated for nitric oxide (NO) suppression activity on interferon gamma (IFN- γ)/ lipopolysaccharides (LPS)-activated RAW 264.7 cells. Among these, compounds **3h**, **7a**, **7d**, and **7e** exhibited comparable or significantly enhancing anti-inflammatory property compared to curcumin ($IC_{50} = 14.69 \pm 0.24 \mu M$), of which compound **7d** (5-methyl-thiophene bearing) displayed the most promising NO inhibitory activity with IC_{50} value of $10.2 \pm 0.6 \mu M$. In order to understand the structure-activity relationship (SAR) to the bioactivity, two-dimensional (2D) and three-dimensional (3D) quantitative structure activity relationship (QSAR) studies were carried out. The structure activity relationship (SAR) study revealed that *para*-hydroxyl group on ring B, and either *meta*-hydroxy or *para*-hydroxy moieties on ring A are crucial for a remarkable anti-inflammatory activity. Based on absorption, distribution, metabolism, excretion and toxicity (ADMET) and toxicity prediction by computer assisted technology (TOPKAT)

analyses, compounds **1c** ($IC_{50} = 26.1 \pm 0.1 \mu M$) is predicted to have a good solubility and absorption, non-mutagenic and to exhibit high blood–brain barrier (BBB) penetration, which indicates a potential as an effective drug candidates for treating the central nervous system (CNS) related disorders.

Due to impressive array of biological profiles of pyrrole and chalcone, we therefore adopted the pyrrole structure and fused it into chalcone scaffold by replacing one of the aromatic rings, in an attempt to develop a new series of chalcone analogues with higher anti-inflammatory potential. All nine synthesized compounds displayed nitric oxide (NO) production suppression effect with IC_{50} values ranging from 21.5 to 62.9 μM . Among them, compounds **9c** (2,5-dimethoxy containing compound) and **9h** (2-methoxy bearing compound) exhibited highest nitric oxide (NO) inhibition effect with IC_{50} values of $21.5 \pm 0.6 \mu M$ and $21.6 \pm 1.1 \mu M$, respectively.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PERKEMBANGAN DAN HUBUNGAN STRUKTUR-AKTIVITI ANALOG
DIARILPENTADIENON DAN KALKON SEBAGAI AGEN ANTI-RADANG
YANG BERPOTENSI**

Oleh

SITI MUNIRAH BINTI MOHD FAUDZI

Mac 2015

Pengerusi : Profesor Madya Faridah Binti Abas, PhD

Institut : Biosains

Kesan-kesan negatif utama yang dikaitkan dengan penggunaan ubat anti radang bukan steroid (NSAIDs) di pasaran kini melibatkan saluran usus gastro, buah pinggang dan masalah pembekuan darah. Kesan-kesan ini telah memacu penemuan ubat-ubatan baru yang lebih selamat digunakan. Dalam mencapai objektif tersebut, kurkumin dilihat sebagai satu alternatif ubat anti radang bukan steroid yang berpotensi memandangkan ianya mempunyai ciri anti radang yang kuat dan bertoksik rendah. Walau bagaimanapun, penggunaan kurkumin dalam ujian klinikal terbatas kerana ciri farmakokinetiknya yang agak lemah. Setakat ini, terdapat beberapa pengubahsuaian yang dilakukan terhadap struktur kurkumin, dan terdapat laporan menunjukkan rangka diarilpentadienon tanpa kumpulan β -diketon, mempengaruhi sifat anti-radang mereka melalui aktiviti perencatan terhadap produksi nitrik oksida (NO) dan perencatan ke atas sitokin-sitokin pro-radang seperti tumor nekrosis alfa (TNF- α) dan interleukin 6 (IL-6).

Di dalam kajian ini, empat puluh lima sebatian menyerupai kurkumin, 1,5-difenilpenta-2,4-dien-1-on dan lima analog pirazolina-diarilpentadienon telah disintesis dan dikaji untuk aktiviti perencatan nitrik oksida (NO) ke atas sel RAW264.7 yang diaktifkan oleh interferon gamma (IFN- γ) dan lipopolisakarida (LPS). Di antara semua, sebatian **3h**, **7a**, **7d**, dan **7e** mempamerkan sifat anti-radang yang setara atau peningkatan yang ketara berbanding kurkumin ($IC_{50} = 14.7 \pm 0.2 \mu M$), di mana sebatian **7d** (mempunyai 5-metil-thiofin) memberikan aktiviti perencatan nitrik oksida (NO) yang paling tinggi dengan nilai $IC_{50} 10.2 \pm 0.6 \mu M$. Dalam usaha untuk memahami hubungan struktur-aktiviti (SAR) dengan bioaktiviti, kajian dua dimesi (2D) dan tiga dimensi (3D) hubungan struktur-aktiviti secara kuantitatif (QSAR) telah dijalankan. Kajian hubungan struktur-aktiviti (SAR) mendedahkan kumpulan hidroksil di kedudukan *para* di gelang B, dan sama ada

kumpulan hidroksil di kedudukan *meta* atau *para* di gelang A adalah penting untuk sifat anti-radang yang tinggi. Berdasarkan analisis penyerapan, pendedaran, metabolisme, penyingkiran dan keracunan (ADMET) dan ramalan keracunan oleh bantuan berteknologi komputer (TOPKAT), sebatian **1c** ($IC_{50} = 26.1 \pm 0.1 \mu M$) diramalkan mempunyai kadar kelarutan dan penyerapan yang tinggi, tidak mutagen dan mempamerkan penembusan halangan otak-darah (BBB) yang tinggi, menunjukkan sebatian berkenaan berpotensi sebagai ubat yang berkesan untuk merawat penyakit berkaitan dengan gangguan sistem saraf pusat.

Berdasarkan profil biologi yang sangat menarik yang ditunjukkan oleh kalkon dan pirol, kami telah menggabungkan struktur pirol ke bahagian kalkon dengan menggantikannya dengan salah satu gelang aromatik, dalam usaha untuk membangunkan siri baharu bagi analog kalkon dengan potensi anti-radang yang lebih tinggi. Kesemua sembilan sebatian yang disintesis merencat produksi nitrik oksida (NO) dengan julat IC_{50} antara 21.5 ke 62.9 μM . Di antara mereka, sebatian **9c** (mempunyai kumpulan 2,5-dimetoksi) dan sebatian **9h** (mempunyai kumpulan 2-metoksi) menunjukkan kesan perencatan nitrik oksida (NO) yang paling tinggi dengan masing-masing mencatat nilai IC_{50} 21.5 \pm 0.6 μM dan 21.6 \pm 1.1 μM .

ACKNOWLEDGEMENTS

First and foremost, I would like to convey my deepest sense of gratitude and sincere thanks to my supervisor, Associate Professor Dr. Faridah Binti Abas, for her sage advice, helpful guidance, constant encouragements and unconditional helps throughout the studies. I would also like to express my deepest gratitude to my prior supervisor, Professor Dr. Md. Nordin Hj. Lajis for his wonderful and constant suggestions and ideas which enabled me to complete my research task.

Besides, I would like to express my sincere appreciation to my co-supervisors, Dr Lam Kok Wai, Dr Syahida binti Ahmad and Professor Dr. Khozirah binti Shaari for their helpful comments and advice throughout the study. A special thanks to Associate Professor Dr Intan Safinar binti Ismail and Dr. Tham Chau Ling for their supports and great advice during the research period.

My appreciations are also conveyed to all staffs and fellow labmates of Laboratory of Natural Product (LHS), especially Mr. Salahudin bin Mohd Raof and Mrs. Siti Nurulhuda binti Mastuki, for their great helps and co-operations throughout my PhD journey. My deepest gratitude are extended to Dr. Leong Sze Wei, for his constructive comments and warm encouragements while conducting this research.

Not forgetting, I would like to thank Universiti Putra Malaysia (UPM) and Ministry of Higher Education (MOHE) for the study leave and financial sponsorship given in past three and a half years. Last but not least, my greatest appreciation is dedicated to my family, Mr. Mohd Faudzi bin Fadzil, Muhamad Affan, Siti Aishah, Muhammad Syafiq, Mrs. Saziah Sidik and Mr. Razak bin Ismail. I especially thank beloved husband, Mohd Abdullah bin Razak and lovely son, Muhammad Naufal bin Mohd Abdullah, for their continuous spiritual support throughout my study. Without you guys, I am nothing today. Thank you so much.

I certify that a Thesis Examination Committee has met on 10th Mac 2015 to conduct the final examination of Siti Munirah binti Mohd Faudzi on her thesis entitled "Development And Structure Activity Relationship Of Diarylpentadienone And Chalcone Analogues As Potential Anti-Inflammatory Agent" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Examination Committee are as follows:

Mohd Aspollah bin Hj Md Sukari, PhD

Professor
Faculty of Science
University Putra Malaysia
(Chairman)

Mohd Basyaruddin bin Abdul Rahman, PhD

Professor
Faculty of Science
University Putra Malaysia
(Internal Examiner)

Sharida binti Fakurazi, PhD

Associate Professor
Faculty of Medicine and Health Sciences
University Putra Malaysia
(Internal Examiner)

Khalid M. Khan, PhD

Professor
H.E.J Research Institute of Chemistry
University of Karachi
Pakistan
(External Examiner)



ZULKARNAIN ZAINAL, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 15 April 2015

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as partial fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Faridah binti Abas, PhD

Associate Professor
Institute of Bioscience
Universiti Putra Malaysia
(Chairman)

Syahida binti Ahmad, PhD

Senior Lecturer
Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Member)

Khozirah binti Shaari, PhD

Professor
Faculty of Science
Universiti Putra Malaysia
(Member)

Lam Kok Wai, PhD

Senior Lecturer
Faculty of Pharmacy
Universiti Kebangsaan Malaysia
(External Member)

Md. Nordin Hj. Lajis, PhD

Professor
Scientific Chairs Unit
Taibah University
(External Member)

BUJANG KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed, or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: _____

Date: _____

Name and Matric No.: Siti Munirah binti Mohd Faudzi (GS28562)

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____ Signature: _____
Name of _____ Name of _____
Chairman of _____ Member of _____
Supervisory _____ Supervisory _____
Committee: _____ Committee: _____

Signature: _____ Signature: _____
Name of _____ Name of _____
Member of _____ Member of _____
Supervisory _____ Supervisory _____
Committee: _____ Committee: _____

Signature: _____
Name of _____
Member of _____
Supervisory _____
Committee: _____

TABLE OF CONTENTS

	Page
ABSTRACT	I
ABSTRAK	III
ACKNOWLEDGEMENT	V
APPROVAL	VI
DECLARATION	VIII
LIST OF TABLES	XII
LIST OF FIGURES	XIII
LIST OF SCHEMES	XVI
LIST OF ABBREVIATIONS	XVII
CHAPTER	
1 INTRODUCTION	
1.1 General	1
1.2 Inflammation	1
1.3 Curcumin	3
1.4 Drug design	4
1.5 Problem statement	5
1.6 Hypothesis	6
1.7 Objectives of study	6
2 LITERATURE REVIEW	
2.1 Inflammation and its mechanism	7
2.2 Curcumin analogues and their biological properties	9
2.3 Diarylpentanoids and their pharmacological properties	12
2.4 Chalcone analogues as anti-inflammatory agents	15
2.5 Drug design and discovery	17
3 MATERIALS AND METHODS	
3.1 Chemicals and reagents	19
3.2 Instrumentations	21
3.3 Chromatographic methods	22
3.4 Synthesis	22
3.5 Biological activity evaluation	23
3.5.1 Anti-inflammatory activity	23
3.6 Computational analyses	25
4 SYNTHESIS OF DIARYLPENTADIENONE AND PYROLYLATED CHALCONE ANALOGUES	
4.1 Synthesis of 1,5-diarylpenta-2,4-dien-1-one	29
4.2 Synthesis of 1,5-diarylpenta-2,4-dien-1-one analogues	38
4.3 Synthesis of pyrazoline analogues of	42

	diarylpentadienone	
4.4	Synthesis of pyrolylated chalcone analogues	52
5	ANTI-INFLAMMATORY ACTIVITY OF DIARYLPENTADIENONE AND PYROLYLATED CHALCONE ANALOGUES	
5.1	NO inhibitory activity of diarylpentadienone analogues in IFN- γ /LPS-induced RAW 264.7 macrophages	61
5.2	NO inhibitory activity of pyrazoline analogues of diarylpentadienone in IFN- γ /LPS-induced RAW 264.7	68
5.3	NO inhibitory activity of pyrolylated chalcone analogues in IFN- γ /LPS-induced RAW 264.7 macrophages	69
6	COMPUTATIONAL STUDIES ON NO INHIBITORY ACTIVITY OF DIARYLPENTADIENONE ANALOGUES	
6.1	Quantity Structure Activity Relationship (QSAR) analyses	73
6.1.1	2D QSAR	73
6.1.2	3D QSAR	77
6.2	ADMET analysis	79
6.3	TOPKAT analysis	81
7	CONCLUSION AND RECOMMENDATIONS	83
	REFERENCES	85
	APPENDICES	99
	BIODATA OF STUDENT	189
	LIST OF PUBLICATIONS	190
	LIST OF CONFERENCES ATTENDED	191

LIST OF TABLES

Table	Page	
3.1	List of chemicals	19
3.2	List of reagents	20
4.1	The ¹ H NMR and ¹³ C-NMR data of 1,5-diphenylpenta-2,4-dien-1-one (1a), measured in CDCl ₃	32
4.2	The ¹ H NMR and ¹³ C-NMR data of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a), measured in CDCl ₃	46
4.3	The ¹ H NMR and ¹³ C-NMR data of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a), measured in acetone-d ₆	55
5.1	NO inhibitory activity and cytotoxicity of 1,5-diphenylpenta-2,4-dien-1-ones analogues in IFN- γ /LPS-induced RAW 264.7	61
5.2	NO inhibitory activity of pyrazoline analogues of diarylpentadienone in IFN- γ /LPS-induced RAW 264.7	69
5.3	NO inhibitory activity of pyrolylated chalcone analogues in IFN- γ /LPS-induced RAW 264.7	70
6.1	IC ₅₀ , pIC ₅₀ , number of rotatable bonds and MFPSA values of active compounds.	73
6.2	Randomization test of GFA equation.	76
6.3	Results of ADMET predictions on selected parameters of selected compounds	81
6.4	Results of TOPKAT analysis of selected compounds	82

LIST OF FIGURES

Figure		Page
1.1	The flow of inflammation cascade	2
1.2	Chemical structures of curcuminoids	3
1.3	Structures of targeted compounds	5
2.1	Basic skeleton of targeted diarylpentadienone analogues	13
2.2	CoMFA contour plot of most active butitaxel analogue	17
3.1	Hemocytometer gridlines	24
4.1	¹ H-NMR spectrum of 1,5-diphenylpenta-2,4-dien-1-one (1a)	31
4.2	¹ H-NMR spectrum (expansion) of 1,5-diphenylpenta-2,4-dien-1-one (1a)	31
4.3	EIMS spectrum of 1,5-diphenylpenta-2,4-dien-1-one (1a)	33
4.4	¹³ C-NMR spectrum of 1,5-diphenylpenta-2,4-dien-1-one (1a)	33
4.5	¹³ C-NMR spectrum (expansion) of 1,5-diphenylpenta-2,4-dien-1-one (1a)	34
4.6	HMBC spectrum of 1,5-diphenylpenta-2,4-dien-1-one (1a)	35
4.7	HMBC spectrum (expansion) of 1,5-diphenylpenta-2,4-dien-1-one (1a)	36
4.8	HSQC spectrum of 1,5-diphenylpenta-2,4-dien-1-one (1a)	37
4.9	¹ H-NMR spectrum of 1,5-bis(4-methoxyphenyl)penta-2,4-dien-1-one (3b)	39
4.10	¹ H-NMR spectrum of 1,5-bis(4-hydroxyphenyl)penta-2,4-dien-1-one (7a)	40
4.11	¹³ C-NMR spectrum of 1,5-bis(4-methoxyphenyl)penta-2,4-dien-1-one (3b)	40
4.12	¹³ C-NMR spectrum of 1,5-bis(4-hydroxyphenyl)penta-2,4-dien-1-one (7a)	41
4.13	EIMS spectrum of 1,5-bis(4-methoxyphenyl)penta-2,4-dien-1-one (3b)	41
4.14	EIMS spectrum of 1,5-bis(4-hydroxyphenyl)penta-2,4-dien-	42

	1-one (7a)	
4.15	¹ H-NMR spectrum of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	44
4.16	Main connectivity of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a) in HMBC and NOESY NMR analysis	45
4.17	¹³ C-NMR spectrum of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	45
4.18	NOESY spectrum of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	47
4.19	HSQC spectrum of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	48
4.20	HSQC spectrum (expansion) of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	49
4.21	HMBC spectrum of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	50
4.22	HMBC spectrum (expansion) of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	51
4.23	EIMS spectrum of 1-acetyl-3-phenyl-5-styryl-2-pyrazoline (8a)	52
4.24	¹ H-NMR spectrum of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	53
4.25	¹³ C-NMR spectrum of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	54
4.26	HSQC spectrum of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	56
4.27	HSQC spectrum (expansion) of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	57
4.28	HMBC spectrum of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	58
4.29	HMBC spectrum (expansion) of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	59
4.30	EIMS spectrum of 3-(3-hydroxy-4-methoxyphenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (9a)	60
6.1	EPFPs equation descriptors	76

6.2	Structural alignment of compounds using template-based technique based on core of analogue 7d	77
6.3	The actual versus predicted activity of training and test sets	78
6.4	Steric contour maps	78
6.5	Electrostatic potential contour maps	79
7.1	Recommended structures of heterocyclic-containing 1,5-diphenylpenta-2,4-dien-1-one analogues as potential anti-inflammatory agent	83
7.2	Recommended structure for potential anti-inflammatory pyrolylated chalcone analogues	84



LIST OF SCHEMES

Scheme		Page
2.1	The NF- κ B activation	9
2.2	Metabolism of curcumin in the body	10
2.3	Claisen-Schmidt condensation reaction	15
2.4	Claisen-Schmidt condensation reaction of chalcone	16
3.1	Flowchart of NO inhibition activity	24
3.2	Flowchart of computational analyses	26
4.1	Retrosynthesis of 1,5-diphenylpenta-2,4-dien-1-one (1a)	30
4.2	Reaction mechanism of Claisen-Schmidt condensation	30
4.3	Total synthesis of series 1-7^a	38
4.4	General synthesis of series 8^a	42
4.5	Reaction mechanism of pyrazoline of diarylpentadienone formation	43
4.6	General synthesis of series 9^a	52
4.7	Reaction mechanism of pyrolylated chalcone formation	53

LIST OF ABBREVIATIONS

A	Alpha
B	Beta
Δ	Chemical shift
AA	Arachidonic acid
AB	Aerobic biodegradability
ACHN	Human renal cell carcinoma
ADMET	Absorption, distribution, metabolism, excretion and toxicity prediction
AM	Ames mutagenicity
AMPK	Adenosine monophosphate-activated protein kinase
AS	Aqueous solubility
ATCC	American Type Culture Collection
BAECs	Bovine aortic endothelial cells
BBB	Blood brain barrier
BBr ₃	Boron tribromide
Bcl-2	B-cell lymphoma 2
BDMC	Bisdemethoxycurcumin
BF ₃ -Et ₂ O	Boron trifluoride-etherate
BHC	benzoylhydrazinocurcumin
br	Broad
¹³ C	Carbon-13
°C	Degree in Celcius
Calu 1	Human non-small cell lung carcinoma
CC	Column chromatography
CCK-8	Cell-counting Kit 8
CDCl ₃	Deuterated chloroform
CH ₂ Cl ₂	Dichloromethane
CHARMm	Chemistry at Harvard Macromolecular Mechanics
CNE2	Human nasopharyngeal carcinoma cell lines
CNS	Central nervous system
CO ₂	Carbon dioxide
CoMFA	Comparative Molecular Field Analysis
COX	Cyclooxygenase
Cu	Copper
CYP2D6	Cytochrome P450 2D6
CYP450	Cytochrome P450
<i>d</i>	Doublet
<i>dd</i>	Doublet of doublet
DHC	dihydrocurcumin
DIMS	Direct infusion mass spectrometry
DMC	Demethoxycurcumin
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	dimethylsulfoxide
DNA	Deoxyribonucleic acid
DR4	Death receptor pathway-4

EI	Electron impact
EIMS	Electron ionization mass spectroscopy
eNOS	Endothelial nitric oxide synthase
EPFP_6	Daylight-style path-based fingerprints
ERK	Extracellular signal receptor-activated kinase
EtOAc	Ethyl acetate
eV	Electron-volt
FBS	Fetal bovine serum
g	gram
GC-MS	Gas Chromatography-Mass Spectroscopy
GFA	Genetic Function Approximation
¹ H	Proton
H460	Human non-cell lung carcinoma
H ₂ SO ₄	Sulphuric acid
HC	hydrazinocurcumin
HCl	Hydrochloric acid
HCT 116	Human colon carcinoma
HepG2	Human hepatoma cell lines
HHC	hexahydrocurcumin
HIA	Human intestinal absorption
HIV	Human immunodeficiency virus
hMAO-B	Human monoamine oxidase-B
HMBC	Heteronuclear multiple-bond correlation spectroscopy
HPLC	High performance liquid chromatography
HSQC	Heteronuclear single-quantum correlation spectroscopy
HT	hepatotoxicity
Hz	Hertz
IC ₅₀	Half maximal inhibitory concentration
IFN- γ	Interferon-gamma
I κ B α	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
IKK	I κ B-kinase
IL	interleukin
iNOS	Inducible nitric oxide synthase
<i>J</i>	Coupling constant in Hz
JNK	c-Jun NH ₂ terminal kinase
kg	Kilogram
KF-Al ₂ O ₃	Potassium fluoride on alumina
KOH	Potassium hydroxide
LOF	Lock-of-fit
LOX	Lipoxygenase
LPS	lipopolysaccharides
<i>m</i>	Multiplet
μ g	Microgram
μ l	Microlitre
μ M	Micromolar
M	Molarity
mg	Miligram

ml	Millilitre
mmol	Milimole
mm	Milimeter
mM	Milimolar
m/z	Mass to charge ratio
MAPK	Mitogen-activated protein kinase
MCF-7	Human breast adenocarcinoma cell lines
MCP	Methylenecyclopropanes
MFPSA	Molecular Fractional Polar Surface Area
MgSO ₄	Magnesium sulphate
MHz	Mega hertz
MIC	Minimum inhibitory concentration
MS	Mass spectroscopy
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NaOH	Sodium hydroxide
NaHCO ₃	Sodium bicarbonate
ND	Not determined
NF-κB	Nuclear factor kappa beta
ng	Nanogram
nm	Nanometre
nM	Nanomolar
NO	Nitric oxide
NOS	Nitric oxide synthase
nNOS	Neuronal nitric oxide synthase
NK	Natural killer
NMR	Nuclear Magnetic Resonance
NSAIDs	Non-steroidal anti-inflammatory drugs
OHC	Octahydrocurcumin
OI	Ocular irritancy
ONOO ⁻	Peroxynitrite
P53	Tumor protein 53
Panc1	Human pancreatic carcinoma
PBS	Phosphate-buffered saline
Pd	Palladium
Pd(OAc) ₂	Palladium (II) acetate
PG	Prostaglandin
Ph ₃ P	Triphenylphosphine
pIC ₅₀	-log IC ₅₀
PLS	Partial least square
PPB	Plasma protein binding
ppm	Part per million
q ²	Cross-validation correlation coefficient
QSAR	Quantitative structure-activity relationship
r ²	Conventional non-cross validation coefficient
RAW 264.7	Macrophage cell lines
RC	Rodent carcinogenicity
R _f	Retention factor
RMS	Root mean square

RNS	Reactive nitrogen species
ROS	Reactive oxygen species
RT	Room temperature
RT-PCR	Reverse-transcriptase-polymerase chain reaction
<i>s</i>	Singlet
SAR	Structure-activity relationship
S.E.M	Standard error of the mean
SI	Skin irritancy
SS	Skin sensitization
SW480	Human colon carcinoma cell lines
<i>t</i>	triplet
THC	tetrahydrocurcumin
TLC	Thin layer chromatography
TMS	tetramethylsilane
TMSCl	Tetramethylsilyl chloride
TNF- α	Tumor necrosis factor alpha
TOPKAT	Toxicity Prediction by Komputer Assisted Technology
Yb(OPf) ₃	Ytterbium perfluorooctane sulfonate

CHAPTER 1

INTRODUCTION

1.1 General

Natural products are structurally diverse and are not commonly found in synthetic compounds. Of the 1184 new chemical entities reported, 60.0% were derived from natural products (Gautam and Jachak, 2009). Based on this, it can be stated that natural products play a dominant role in contributing to the diversity of chemical entities, which in turn enhanced the discovery and development efforts of drugs in combating human diseases. In addition, traditional medicine and natural products offer great opportunities for the identification and discovery of biologically active compounds. These compounds may be further developed into agents that can be used in the treatment of human diseases, especially triggered by inflammatory process.

Since ancient times, humans suffering from inflammatory reactions and diseases were treated with phytochemicals such as myrtle and willow tree bark, which were used in the treatment of stiff and painful joints (Vonkeman et al., 2010). Plants contain various complex mixtures of bioactive molecules, some of which may possess beneficial effects that can improve body resistance to cellular stress or exogenous factors, while also preventing the cytotoxicity of various agents.

The biologically active compounds that have shown significant anti-inflammatory properties exhibit a wide range of structural diversity and can be classified as alkaloids, steroids, flavonoids, terpenoids, polyphenolics, phenylpropanoids, fatty acids and lipids, and various miscellaneous products (Gautam and Jachak, 2009).

In recent years, the use of natural products has attracted scientific and public attention for its use in the prevention or treatment of chronic diseases. It has been shown that the consumption of natural products helps reduce the risk of developing pathological conditions such as cancer, cardiovascular illnesses, nervous system disorders, as well as genetic and inflammatory diseases (Jurenka, 2009; Newman and Cragg, 2007).

1.2 Inflammation

Inflammation is a complex component of an organism's response to a variety of stimuli including both biological and chemical stimuli, physical damage, ultra irradiation, immune reactions, and microbial invasions (Ferrero-Miliani et al., 2007). The features of inflammation are warmth, swelling, pain, redness, and loss of function. Further looks into the processes that occur in response to an injury reveal that the immune system's cells, such as leukocytes migrate via chemotaxis to the injury site in an orchestrated sequence. This movement is mediated by various cytokines and acute phase proteins to remove foreign materials through phagocytosis, subsequently initiating the healing process (Figure 1.1). It has also been found that prolonged exposure to a stimulus can lead to the onset of a chronic phase (Lin and Karin, 2007).




Figure 1.1 The flow of inflammatory cascade (uic.edu, 2011)

It has been reported that chronic inflammation may lead to the development of numerous diseases including cancer (Yamamoto and Gaynor, 2001), chronic asthma (Murdoch and Lloyd, 2010), cardiovascular diseases (Libby, 2006), diabetes (Lobner and Fuchtenbusch, 2004), autoimmune diseases (Ishihara and Hirano, 2002), atherosclerosis (Hansson et al., 2006), allergies (Fan et al., 2005), rheumatoid arthritis (Choy and Panayi, 2001), inflammatory bowel disease (Itzkowitz and Yio, 2004), psoriasis (Dowlatshahi et al., 2013), multiple sclerosis (Kidd, 2001), and may also contribute to aging (Chung et al., 2001).

To block the inflammatory cascade, the source of molecular targets must be antagonized. The anti-inflammatory targets of anti-inflammatory drugs are cyclooxygenase (COX-1, COX-2) (Dinarello, 2010), cytokines and cytokine receptors, tumour necrosis factor (TNF)- α (Popa et al., 2007), interleukin (IL)- 1β (Dinarello et al., 2012), and interferon (IFN)- γ (Muhl and Pfeilschifter, 2003), as well as G-protein-coupled receptors (Sun and Ye, 2012) histamine 1 (MacGlashan, 2003) and cysteinyl leukotriene 1 (Holgate et al., 2003). In addition, the transcription factor, nuclear factor (NF)- κ B (Lawrence, 2009), mitogen-activated protein kinases (MAPKs) (Kaminska, 2005), c-Jun-N-terminal kinase (JNK) (Waetzig et al., 2005), and p38 kinases (Schieven, 2005) have also been described as potential anti-inflammatory targets. Several reviews have described natural anti-inflammatory products that are restricted to a particular molecular target, such as lipoxygenases (LOXs) (Martel-Pelletier et al., 2003), arachidonic acid (AA) cascade (Ferrandiz and Alcaraz, 1991), nitric oxide (NO) (Cirino et al., 2006), and NF- κ B, or TNF- α . There have also been reports showing that inhibitor of prostaglandin (PG) biosynthesis and NO production were considered as potential anti-inflammatory and cancer chemopreventive agents (Gautam and Jachak, 2009).

NO is a short-lived key molecular signalling involved in host defences and immune responses. NO is produced through oxidative deamination of L-arginine to L-citrulline, catalyzed by NO synthase (NOS) family, in NADPH and oxygen-dependent process (Ma et al., 2015). Three major isoforms of NOS are neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). In chronic inflammation, the activated pro-

inflammatory cytokines or lipopolysaccharide (LPS) induce iNOS to produce a high level of NO in response to inflammatory signals.

NO aggressively reacts with superoxide to produce peroxynitrite (ONOO^-), a member of reactive nitrogen species (RNS), which also forms another extremely reactive oxygen species (ROS), hydroxyl radicals. Hence, uncontrollable production of NO will lead to an elevated level of RNS and ROS, which contributed towards various DNA modifications, cellular injuries, genotoxicity and carcinogenesis (Surh et al., 2001).

Therefore, overproduction of NO is one of the important factors involved in a variety of diseases including cancer (Ridnour et al., 2008), cardiovascular disorder (Naseem, 2005), asthma (Fitzpatrick et al., 2009) and rheumatoid arthritis (Hensley et al., 1997). Based on this reason, pharmacological reduction of NO production is a promising strategy in developing effective drugs for inflammation-related diseases. To name a few, ibuprofen, indomethacin, diclofenac, and piroxicam are common analgesic NSAIDs used in treatment of arthritis which possess strong anti-inflammatory characters due to their capability in inhibiting various pro-inflammatory enzymes including COX-1, COX-2 and iNOS (Berg et al., 1999).

1.3 Curcumin

Curcumin, 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (Figure 1.2), generally known as diferuloyl methane, is a hydrophobic polyphenol, yellow compound, isolated from the rhizome of the herb *Curcuma longa* Linn. The three major curcuminoids isolated from turmeric are curcumin (**1**, 94%), demethoxycurcumin (**2**, 6%), and bisdemethoxycurcumin (**3**, 0.3%) (Chattopadhyay et al., 2004).




Figure 1.2 Chemical structures of curcuminoids.

Curcumin and its analogues have been found to exhibit various biological and pharmacological properties including anti-inflammatory, antioxidant, antiviral, antimicrobial, chemo-preventive, antiangiogenic, antiandrogenic, and anticancer properties (Bisht et al., 2010). Anti-inflammatory properties of curcumin are manifested by suppressing the activation and production of nuclear factor kappa-beta ($\text{NF-}\kappa\text{B}$) (Singh and Aggarwal, 1995), cyclooxygenase-2 (COX-2) and other pro-inflammatory mediators, such as tumor-necrosis factor alpha ($\text{TNF-}\alpha$) and interleukin-6 (IL-6) (Maheshwari et al., 2006). However, poor bioavailability has limited the practical use of curcumin.

Several approaches have been developed to improve the bioavailability of curcumin, including nanoparticle-encapsulation (Mulik et al., 2010), liposomal formulations (Anand et al., 2007) and structure modifications (Aggarwal and Mishra, 2010).

1.4 Drug design

Once a target and testing system are identified, the next stage is to find and develop a good lead compound that may exhibit the desired pharmacological activity. Today's marketed medicines are either obtained directly from a natural source or were developed from a lead compound originally obtained from natural products. The lead compounds can be discovered through various ways, including screening of natural products, particularly from the plant kingdom. Clinically useful drug, paclitaxel (Taxol) have recently been isolated from pacific yew tree. Various studies have reported Paclitaxel as an effective anticancer agent against lung, ovarian, breast and liver cancer (Priyadarshini and Keerthi Aparajitha, 2012).

The alternative approach in finding a lead compounds is through virtual screening, which libraries of available small molecules were docked into the target of interest *in silico* and scored based on their interaction with the site (Anderson, 2003). Virtual screening is generally divided into two methods, the structure-based and ligand-based. The structure-based method is very useful when the target is available, led to the detailed investigation of target-ligand interaction mode, thus the rational design of novel chemical structures with improved properties was carried out. Equally, the ligand-based technique that uses the predictive compound activity models based on previous experimental data is also attractive. The potential of virtual screening has been demonstrated by the identification and development of patented drug candidate SC12267 as a rheumatoid arthritis agent (Clark, 2006).



Once a small molecule has been identified, it must be evaluated before proceed to the next stages. Leads are first evaluated visually through computer analysis and often been optimized at this step for affinity enhancement (Anderson, 2003). Leads also been evaluated for their orally bioavailability properties using the Lipinski rules (Lipinski et al., 1997), which stated 'lead-like' compounds generally have MW < 500, HBA < 10, HBD < 5 and log P < 5. Veber et al., (2002) also stated that number of rotatable bond should be less than 10 to increase the oral bioavailability. Finally, the lead compounds were tested for their biological activities. The promising lead compounds often re-enter the structural determination process in finding the exact binding mode and further structurally optimized until becomes evident.

1.5 Problem statement

The main adverse effects of current NSAIDs, involved the gastrointestinal tract, kidney and blood clotting has lead to the discovery of new NSAIDs with improved safety profile. Curcumin could be serves as potential NSAID candidate based on its strong anti-inflammatory property and low toxicity. However, its utilization in clinical trials was restricted due to poor pharmacokinetic properties. Recent studies reported the mono carbonyl diarylpentanoid analogues possess enhanced stability *in vitro* and improved pharmacokinetic profiles *in vivo* particularly in anti-inflammatory activity (Liang et al., 2009). Hence, this has prompted us to design smaller and less complex diarylpentanoid-related compounds due to the fact that smaller molecules are more likely to bind readily to the binding sites of selected target, and thus improve the activity.

To the best of our knowledge, none of the studies incorporated the $\alpha,\beta,\gamma,\delta$ -unsaturated ketone moiety in a diarylpentadienone scaffold in the evaluation of the anti-inflammatory properties, particularly with regards to NO inhibition activity. The general structures of the targeted compounds are shown in Figure 1.3. The design of new diarylpentadienone system was primarily based on steric and electronic properties of substituent. The selected functional groups were appended on different positions of both ring A and ring B to examine their important influence towards NO inhibitory activity. Also, by replacing an aromatic moiety of ring A with heteroaromatic ring able to introduce the possibility of hydrogen bonding interaction and improve the ligand-receptor interactions of diarylpentadienone system, resulted better activity.

In addition, we have designed a new series of diarylpentadienone derivatives by introducing pyrazoline ring into the system (Figure 1.3) which might increase their bioavailability through the better rigidity, thus give a positive effect on selected activity (Veber et al., 2002). Besides that, we also synthesized a series of pyrrolylated-chalcone analogues (Figure 1.3) with a shorter linker chain in comparison to diarylpentadienone analogues to observe their flexibility impact towards NO inhibition activity. Moreover, no computational analyses (2D and 3D QSAR, ADMET and TOPKAT) of these diarylpentadienone analogues and their NO inhibitory properties have previously been studied.




Figure 1.3 Structures of targeted compounds

1.6 Hypothesis

In this study, we are focusing on design strategies in optimizing the interaction of diarylpentadienone analogues with its target in order to produce the desired anti-inflammation property, by studying the effect of various functional groups at different positions of diarylpentadienone rings on NO inhibitory effects. Previous studies has been reported that introduction of polar group at *para*-position on phenyl ring of curcuminoid proven to be essential for anti-inflammatory activity (Orlikova et al., 2011). Based on this, we predicted that diarylpentadienone analogues with *para*-hydroxyl moiety will show a remarkable NO inhibition activity. Rigidification has been used to enhance the activity of drug or to reduce its adverse effects. Therefore, we are trying to study the effect of rigidity on the diarylpentadienone scaffold by incorporating the pyrazoline ring into the system. We expected that this pyrazoline-diarylpentadienone analogues will displayed a comparable NO inhibitory performance to curcumin. The shortening of five-carbon spacer to three-carbon chain length to forms the chalcone analogues will reduced flexibility and might improve the binding interactions with the active site, thus enhance the targeted anti-inflammatory activity.

1.7 Objectives of this study

1. To design and synthesize diarylpentadienone, and pyrrolylated chalcone analogues.
2. To evaluate the anti-inflammatory property of diarylpentadienone and pyrrolylated chalcone analogues using the NO inhibitory activity.
3. To identify active compounds of diarylpentadienone and pyrrolylated chalcone analogues based on SAR studies.
4. To analyse 2D and 3D QSAR, ADMET and TOPKAT of diarylpentadienone analogues.

REFERENCES

- Adams, B. K., Ferstl, E. M., Davis, M. C., Herold, M., Kurtkaya, S., Camalier, R. F., and Shoji, M. (2004). Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. *Bioorganic & Medicinal Chemistry*. 12(14): 3871-3883.
- Aggarwal, D. K., and Mishra, P. K. (2010). Curcumin and its analogues: potential anticancer agents. *Medicinal research reviews*. 30 : 818-860.
- Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. 2002. Innate Immunity. *Molecular Biology of the Cell*. 4th edition. New York: Garland Science
- Ali, S. M., Hoemann, M. Z., Aube, J., Georg, G. I., Mitscher, L. A., and Jayasinghe, L. R. (1997). Butitaxel analogues: synthesis and structure-activity relationships. *Journal of Medicinal Chemistry*. 40(2) : 236-241.
- Amin, K. (2012). The role of mast cells in allergic inflammation. *Respiratory Medicine*. 106(1): 9-14.
- Anand, P., Thomas, S. G., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Sung, B., and Aggarwal, B. B. (2008). Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. *Biochemical Pharmacology*. 76(11): 1590-1611.
- Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. *Molecular pharmaceutics*. 4 : 807-818.
- Anderson, A. C. (2003). The process of structure-based drug design. *Chemistry & Biology*. 10 : 787-797.
- Anto, R. J., George, J., Babu, K. V., Rajasekharan, K. N., and Kuttan, R. (1996). Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. *Mutation Research*. 370(2): 127-131.
- Bandgar, B. P., Gawande, S. S., Bodade, R. G., Gawande, N. M., and Khobragade, C. N. (2009). Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents. *Bioorganic & Medicinal Chemistry*. 17(24): 8168-8173.
- Bandgar, B. P., Patil, S. A., Korbade, B. L., Nile, S. H., and Khobragade, C. N. (2010). Synthesis and biological evaluation of beta-chloro vinyl chalcones as inhibitors of TNF-alpha and IL-6 with antimicrobial activity. *European Journal of Medicinal Chemistry*. 45(6): 2629-2633.
- Barthelemy, S., Vergnes, L., Moynier, M., Guyot, D., Labidalle, S., and Bahraoui, E. (1998). Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. *Research of Virolog.*, 149(1): 43-52.

- Batovska, D., Parushev, S., Slavova, A., Bankova, V., Tsvetkova, I., Ninova, M., and Najdenski, H. (2007). Study on the substituents' effects of a series of synthetic chalcones against the yeast *Candida albicans*. *European Journal of Medicinal Chemistry*. 42(1): 87-92.
- Battilocchio, C., Poce, G., Alfonso, S., Porretta, G. C., Consalvi, S., Sautebin, L., and Biava, M. (2013). A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. *Bioorganic & Medicinal Chemistry*. 21(13): 3695-3701.
- Beutler, B., and Rietschel, E. T. (2003). Innate immune sensing and its roots: the story of endotoxin. *Nature Reviews of Immunology*. 3(2): 169-176.
- Berg, J., Fellier, H., Christoph, T., Grarup, J., and Stimmeder, D. (1999). The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. *Inflammation research : official journal of the European Histamine Research Society*. 48 : 369-379.
- Bisht, K., Wagner, K. H., and Bulmer, A. C. (2010). Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. *Toxicology*. 278(1): 88-100.
- Boehm, U., Klamp, T., Groot, M., and Howard, J. C. (1997). Cellular responses to interferon-gamma. *Annual Review of Immunology*. 15: 749-795.
- Bogdan, C. (2001). Nitric oxide and the immune response. *Nature Immunology*. 2(10): 907-916.
- Chattopadhyay, I., Biswas, K., Bandyopadhyay, U., and Banerjee, R.K. (2004). Turmeric and curcumin: Biological actions and medicinal applications. *Current Science*. 87(1): 44-53.
- Chen, C. C., and Wang, J. K. (1999). p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. *Molecular Pharmacology*. 55(3): 481-488.
- Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., and Hsieh, C. Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Research*. 21(4B): 2895-2900.
- Cheng, Z., Lin, C., Hwang, T., and Teng, C. (2001). Brousochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages. *Biochemical Pharmacology*. 61(8): 939-946.
- Cho, Y. C., Kim, H. J., Kim, Y. J., Lee, K. Y., Choi, H. J., Lee, I. S., and Kang, B. Y. (2008). Differential anti-inflammatory pathway by xanthohumol in IFN-gamma and LPS-activated macrophages. *International Immunopharmacological*. 8(4): 567-573.

- Choudhuri, T., Pal, S., Agwarwal, M. L., Das, T., and Sa, G. (2002). Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. *FEBS Letters*. 512(1-3): 334-340.
- Choy, E. H., and Panayi, G. S. (2001). Cytokine pathways and joint inflammation in rheumatoid arthritis. *The New England Journal of Medicine*. 344(12): 907-916.
- Chung, H. Y., Kim, H. J., Kim, J. W., and Yu, B. P. (2001). The inflammation hypothesis of aging: molecular modulation by calorie restriction. *Annals of the New York Academic of Science*. 928: 327-335.
- Cirino, G., Distrutti, E., and Wallace, J. L. (2006). Nitric oxide and inflammation. *Inflammation & Allergy Drug Targets*. 5(2): 115-119.
- Clark, D. E. (2006). What has computer-aided molecular design ever done for drug discovery? *Expert Opinion on Drug Discovery*. 1 : 103-110.
- Climent, M. J., Corma, A., Iborra, S., and Velty, A. (2004). Activated hydrotalcites as catalysts for the synthesis of chalcones of pharmaceutical interest. *Journal of Catalysis*. 221(2): 474-482.
- Cooke, S. A., K. Corlett, G., and C. Legon, A. (1998). Rotational spectrum of thiophene HCl. Does thiophene act as an aromatic π -type electron donor or an n-type electron donor in hydrogen-bond formation? *Journal of the Chemical Society, Faraday Transactions*. 94(11): 1565-1570.
- Dannhardt, G., and Kiefer, W. (2001). Cyclooxygenase inhibitors--current status and future prospects. *European Journal of Medicinal Chemistry*. 36(2): 109-126.
- Desideri, N., Fioravanti, R., Proietti Monaco, L., Biava, M., Yanez, M., Ortuso, F., and Alcaro, S. (2013). 1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors. *European Journal of Medicinal Chemistry*. 59: 91-100.
- Dikshit, M., Rastogi, L., Shukla, R., and Srimal, R. C. (1995). Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. *Indian Journal of Medical Research*. 101: 31-35.
- Dinarello, C. A. (2010). Anti-inflammatory Agents: Present and Future. *Cell*. 140(6): 935-950.
- Dinarello, C. A., Simon, A., and van der Meer, J. W. (2012). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nature Reviews Drug Discovery*. 11(8): 633-652.
- Dorai, T., and Aggarwal, B. B. (2004). Role of chemopreventive agents in cancer therapy. *Cancer Letters*. 215(2): 129-140.

- Dowlatshahi, E. A., van der Voort, E. A., Arends, L. R., and Nijsten, T. (2013). Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. *British Journal of Dermatology*. 169(2): 266-282.
- Duncia, J. V., Santella, J. B., Higley, C. A., Pitts, W. J., Wityak, J., Fietze, W. E., and Olson, R. E. (1998). MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. *Bioorganic & Medicinal Chemistry Letters*. 8(20): 2839-2844.
- El-Sayed, M. A., Abdel-Aziz, N. I., Abdel-Aziz, A. A., El-Azab, A. S., and El-Tahir, K. E. (2012). Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2. *Bioorganic & Medicinal Chemistry*. 20(10): 3306-3316.
- Fan, J., Heller, N. M., Gorospe, M., Atasoy, U., and Stellato, C. (2005). The role of post-transcriptional regulation in chemokine gene expression in inflammation and allergy. *European Respiratory Journal*. 26(5): 933-947.
- Ferrandiz, M. L., and Alcaraz, M. J. (1991). Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. *Agents and Actions*. 32(3-4): 283-288.
- Ferrero-Miliani, L., Nielsen, O.H., Andersen, P.S., and Girardin, S.E. (2007). Chronic inflammation : importance of NOD2 and NALP3 in interleukin-1 beta generation. *Clinical and Experimental Immunology*. 146(2): 227-235.
- Fitzpatrick, A. M., Brown, L. A., Holguin, F., and Teague, W. G. (2009). Levels of nitric oxide oxidation products are increased in the epithelial lining fluid of children with persistent asthma. *Journal of allergy and clinical immunology*. 124 : 990-996 e991-999.
- Frimayanti, N., Lee, V.S., M. Zain, S., A. Wahab, H., and Abd. Rahman, N. (2014). 2D, 3D-QSAR, and pharmacophore studies of thiazolidine-4-carboxylic acid derivatives as neuraminidase inhibitors in H₃N₂ influenza virus. *Medicinal Chemistry Research*. 23(3):1447-1453.
- Funakoshi-Tago, M., Nakamura, K., Tsuruya, R., Hatanaka, M., Mashino, T., Sonoda, Y., and Kasahara, T. (2010). The fixed structure of Licochalcone A by alpha, beta-unsaturated ketone is necessary for anti-inflammatory activity through the inhibition of NF-kappaB activation. *International Immunopharmacological*. 10(5): 562-571.
- Gaestel, M., Kotlyarov, A., and Kracht, M. (2009). Targeting innate immunity protein kinase signalling in inflammation. *Nature Reviews Drug Discovery*. 8(6): 480-499.
- Galley, H. F., and Webster, N. R. (1996). The immuno-inflammatory cascade. *British Journal of Anaesthesia*. 77(1): 11-16.

- Gautam, R., and Jachak, S. M. (2009). Recent developments in anti-inflammatory natural products. *Medicinal Research Reviews*. 29(5): 767-820.
- Gerhauser, C., Alt, A., Heiss, E., Gamal-Eldeen, A., Klimo, K., Knauft, J., and Becker, H. (2002). Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. *Molecular Cancer Therapeutics*. 1(11): 959-969.
- Handler, N., Jaeger, W., Puschacher, H., Leisser, K., and Erker, T. (2007). Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors. *Chemical & Pharmaceutical Bulletin (Tokyo)*. 55(1): 64-71.
- Hansson, G. K., Robertson, A. K., and Soderberg-Naucler, C. (2006). Inflammation and atherosclerosis. *Annual Review of Pathology Mechanisms of Disease*. 1: 297-329.
- Hayden, M. S., and Ghosh, S. (2004). Signaling to NF-kappaB. *Genes & Development*. 18(18): 2195-2224.
- Hensley, K., Tabatabaie, T., Stewart, C. A., Pye, Q., and Floyd, R. A. (1997). Nitric oxide and derived species as toxic agents in stroke, AIDS dementia, and chronic neurodegenerative disorders. *Chemical research in toxicology*. 10 : 527-532.
- Herencia, F., Ferrandiz, M. L., Ubeda, A., Dominguez, J. N., Charris, J. E., Lobo, G. M., and Alcaraz, M. J. (1998). Synthesis and anti-inflammatory activity of chalcone derivatives. *Bioorganic & Medicinal Chemistry Letters*. 8(10): 1169-1174.
- Herencia, F., Ferrandiz, M. L., Ubeda, A., Guillen, I., Dominguez, J. N., Charris, J. E., and Alcaraz, M. J. (2001). 4-dimethylamino-3',4'-dimethoxychalcone downregulates iNOS expression and exerts anti-inflammatory effects. *Free Radical Biology & Medicine*. 30(1): 43-50.
- Holgate, S. T., Peters-Golden, M., Panettieri, R. A., and Henderson, W. R., Jr. (2003). Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. *J Journal of Allergy and Clinical Immunology*. 111(1 Suppl), S18-34; discussion S34-16.
- Holmes, F. A., Kudelka, A. P., Kavanagh, J. J., Huber, M. H., Ajani, J. A., and Valero, V. 2009. Chapter 3 – Taxane Anticancer Agents. *Current Status of Clinical Trials with Paclitaxel and Docetaxel*. pp. 31-57. *ACS Symposium Series*, Vol. 583.
- Ishihara, K., and Hirano, T. (2002). IL-6 in autoimmune disease and chronic inflammatory proliferative disease. *Cytokine & Growth Factor Reviews*. 13(4-5): 357-368.

- Itzkowitz, S. H., and Yio, X. (2004). Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 287(1): G7-17.
- Jin, F., Jin, X. Y., Jin, Y. L., Sohn, D. W., Kim, S. A., Sohn, D. H., and Kim, H. S. (2007). Structural requirements of 2',4',6'-tris(methoxymethoxy) chalcone derivatives for anti-inflammatory activity: the importance of a 2'-hydroxy moiety. *Archives of Pharmaceutical Research*. 30(11): 1359-1367.
- Jung, E. M., Lim, J. H., Lee, T. J., Park, J. W., Choi, K. S., and Kwon, T. K. (2005). Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). *Carcinogenesis*. 26(11): 1905-1913.
- Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Alternative Medicine Review*. 14(2): 141-153.
- Kaminska, B. (2005). MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. *Biochimica et Biophysica Acta*. 1754(1-2): 253-262.
- Kerns, E. H., and Di, L. 2008. Chapter 10 - Blood-Brain Barrier. *Drug-like Properties: Concepts, Structure Design and Methods*. pp. 122-136. San Diego: Academic Press.
- Kerns, E. H., and Di, L. 2008. Chapter 15 - Cytochrome P450 Inhibition. *Drug-like Properties: Concepts, Structure Design and Methods*. pp. 197-208. San Diego: Academic Press.
- Kerns, E. H., and Di, L. 2008. Chapter 17 - Toxicity. *Drug-like Properties: Concepts, Structure Design and Methods*. pp. 215-223. San Diego: Academic Press.
- Khanna, I. K., Weier, R. M., Yu, Y., Collins, P. W., Miyashiro, J. M., Koboldt, C. M., and Isakson, P. C. (1997). 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. *Journal of Medicinal Chemistry*. 40(11): 1619-1633.
- Kidd, P. M. (2001). Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. *Alternative Medicine Review*. 6(6): 540-566.
- Kim, N. Y., Pae, H. O., Oh, G. S., Kang, T. H., Kim, Y. C., Rhew, H. Y., and Chung, H. T. (2001). Butein, a plant polyphenol, induces apoptosis concomitant with increased caspase-3 activity, decreased Bcl-2 expression and increased Bax expression in HL-60 cells. *Pharmacology & Toxicology*. 88(5): 261-266.
- Kim, Y. H., Kim, J., Park, H., and Kim, H. P. (2007). Anti-inflammatory activity of the synthetic chalcone derivatives: inhibition of inducible nitric oxide

synthase-catalyzed nitric oxide production from lipopolysaccharide-treated RAW 264.7 cells. *Biological & Pharmaceuticals Bulletin*. 30(8): 1450-1455.

- Kiso, Y., Suzuki, Y., Watanabe, N., Oshima, Y., and Hikino, H. (1983). Antihepatotoxic principles of *Curcuma longa* rhizomes. *Planta Medica*. 49(3): 185-187.
- Ko, H. H., Tsao, L. T., Yu, K. L., Liu, C. T., Wang, J. P., and Lin, C. N. (2003). Structure-activity relationship studies on chalcone derivatives. the potent inhibition of chemical mediators release. *Bioorganic & Medicinal Chemistry*. 11(1): 105-111.
- Kulkarni, P., Wagh, P., and Zubaidha, P. (2012). An improved and eco-friendly method for the synthesis of flavanone by the cyclization of 2'-hydroxy chalcone using methane sulphonic acid as catalyst. *Chemistry Journal*. 2(3): 106-110.
- Kumar, S., Dubey, K. K., Tripathi, S., Fujii, M., and Misra, K. (2000). Design and synthesis of curcumin-bioconjugates to improve systemic delivery. *Nucleic Acids Symposium Series* 44: 75-76.
- Kumar, S., Sharma, A., Madan, B., Singhal, V., and Ghosh, B. (2007). Isoliquiritigenin inhibits IkappaB kinase activity and ROS generation to block TNF-alpha induced expression of cell adhesion molecules on human endothelial cells. *Biochemical Pharmacology*. 73(10): 1602-1612.
- Lam, K. W., Tham, C., Liew, C., Syahida, A., Abdul Rahman, M. B., Israf, D., and Lajis, N. (2012). Synthesis and evaluation of DPPH and anti-inflammatory activities of 2,6-bisbenzylidenecyclohexanone and pyrazoline derivatives. *Medicinal Chemistry Research*. 21(3): 333-344.
- Lam, K. W., Uddin, R., Liew, C. Y., Tham, C. L., Israf, D. A., Syahida, A., and Lajis, N. H. (2012). Synthesis and QSAR analysis of chalcone derivatives as nitric oxide inhibitory agent. *Medicinal Chemistry Research*. 21(8): 1953-1966.
- Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harbor Perspective in Biology*. 1(6): a001651.
- Lee, K. H., Ab Aziz, F. H., Syahida, A., Abas, F., Shaari, K., Israf, D. A., and Lajis, N. H. (2009). Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. *European Journal of Medicinal Chemistry*. 44(8): 3195-3200.
- Lee, S. H., Seo, G. S., and Sohn, D. H. (2004). Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase by butein in RAW 264.7 cells. *Biochemical and Biophysical Research Communications*. 323(1): 125-132.

- Levai, A., Patonay, T., Silva, A. M. S., Pinto, D. C. G. A., and Cavaleiro, J. A. S. (2002). Synthesis of 3-aryl-5-styryl-2-pyrazolines by the reaction of (E,E)-cinnamylideneacetophenones with hydrazines and their oxidation into pyrazoles. *Journal of Heterocyclic Chemistry*. 39(4): 751-758.
- Liang, G., Shao, L., Wang, Y., Zhao, C., Chu, Y., Xiao, J., and Yang, S. (2009). Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. *Bioorganic and Medicinal Chemistry*. 17(6): 2623-2631.
- Liang, G., Yang, S., Jiang, L., Zhao, Y., Shao, L., Xiao, J., and Li, X. (2008). Synthesis and anti-bacterial properties of mono-carbonyl analogues of curcumin. *Chemical & Pharmaceutical Bulletin (Tokyo)*. 56(2): 162-167.
- Libby, P. (2006). Inflammation and cardiovascular disease mechanisms. *American Journal of Clinical Nutrition*. 83(2): 456S-460S.
- Lin, W.W., and Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation and cancer. *Journal of Clinical Investigation*. 117: 1175-1183.
- Lin, Y. M., Zhou, Y., Flavin, M. T., Zhou, L. M., Nie, W., and Chen, F. C. (2002). Chalcones and flavonoids as anti-tuberculosis agents. *Bioorganic & Medicinal Chemistry*. 10(8): 2795-2802.
- Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 46(1-3): 3-26.
- Lipinski, C., Lombardo, F., Dominy, B., and Feeney, P. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*. 23 : 3-25
- Lobner, K., and Fuchtenbusch, M. (2004). Inflammation and diabetes. *Journal of MMW Fortschritte der Medizin*. 146(35-36): 32-33, 35-36.
- Lorsbach, R. B., Murphy, W. J., Lowenstein, C. J., Snyder, S. H., and Russell, S. W. (1993). Expression of the nitric oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-gamma and lipopolysaccharide. *Journal of Biology Chemistry*. 268(3): 1908-1913.
- Ma, L., He, L., Lei, L., Liang, X., Lei, K., Zhang, R., Yang, Z., and Chen, L. (2015). Synthesis and biological evaluation of 5-nitropyrimidine-2,4-dione analogues as inhibitors of nitric oxide and inos activity. *Chemical Biology & Drug Design*. 85(3) : 296-299
- MacGlashan, D. Jr. (2003). Histamine: A mediator of inflammation. *Journal of Allergy and Clinical Immunology*. 112(4 Suppl): S53-59.

- Maheshwari, R. K., Singh, A. K., Gaddipati, J., and Srimal, R. C. (2006). Multiple biological activities of curcumin: a short review. *Life sciences*. 78 : 2081-2087.
- Mandhane, S. N., Shah, J. H., and Thennati, R. (2011). Allergic rhinitis: an update on disease, present treatments and future prospects. *International Immunopharmacological*. 11(11): 1646-1662.
- Manna, F., Chimenti, F., Bolasco, A., Filippelli, A., Palla, A., Filippelli, W., and Mercantini, R. (1992). Anti-inflammatory, analgesic and antipyretic 4,6-disubstituted 3-cyanopyridine-2-ones and 3-cyano-2-aminopyridines. *European Journal of Medicinal Chemistry*. 27(6): 627-632.
- Maroon, J.C., Bost, J.W., and Maroon, A. (2010). Natural anti-inflammatory agents for pain relief. *Surgical Neurology International*. 1: 80-89.
- Martel-Pelletier, J., Lajeunesse, D., Reboul, P., and Pelletier, J. P. (2003). Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. *Annals of Rheumatic Diseases*. 62(6): 501-509.
- Martich, G. D., Boujoukos, A. J., and Suffredini, A. F. (1993). Response of man to endotoxin. *Immunobiology*. 187(3-5): 403-416.
- Maskrey, B. H., Megson, I. L., Whitfield, P. D., and Rossi, A. G. (2011). Mechanisms of resolution of inflammation: a focus on cardiovascular disease. *Arteriosclerosis, Thrombosis and Vascular Biology*. 31(5): 1001-1006.
- McOmie, J. F., Watts, M., and West, D. E. (1968). Demethylation of aryl methyl ethers by boron tribromide. *Tetrahedron*. 24(5): 2289-2292.
- Mishra, S., Kapoor, N., Mubarak Ali, A., Pardhasaradhi, B. V., Kumari, A. L., Khar, A., and Misra, K. (2005). Differential apoptotic and redox regulatory activities of curcumin and its derivatives. *Free Radical Biology & Medicine*. 38(10): 1353-1360.
- Mishra, S., Karmodiya, K., Surolia, N., and Surolia, A. (2008). Synthesis and exploration of novel curcumin analogues as anti-malarial agents. *Bioorganic & Medicinal Chemistry*. 16(6): 2894-2902.
- Muhl, H., and Pfeilschifter, J. (2003). Anti-inflammatory properties of pro-inflammatory interferon-gamma. *International Immunopharmacological*. 3(9): 1247-1255.
- Mukhopadhyay, A., Banerjee, S., Stafford, L. J., Xia, C., Liu, M., and Aggarwal, B. B. (2002). Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. *Oncogene*. 21(57): 8852-8861.
- Mukhopadhyay, A., Basu, N., Ghatak, N., and Gujral, P. K. (1982). Anti-inflammatory and irritant activities of curcumin analogues in rats. *Agents Actions*. 12(4): 508-515.

- Mulik, R. S., Monkkonen, J., Juvonen, R. O., Mahadik, K. R., and Paradkar, A. R. (2010). Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. *International Journal of Pharmaceutics*. 398 : 190-203.
- Murdoch, J. R., and Lloyd, C. M. Chronic inflammation and asthma. *Mutation Research*. 690(1-2): 24-39.
- Murugan, P., and Pari, L. (2005). Effect of tetrahydrocurcumin on erythromycin estolate-induced lipid peroxidation in rats. *Journal of Basic and Clinical Physiology and Pharmacology*. 16(1): 1-15.
- Naseem, K. M. (2005). The role of nitric oxide in cardiovascular diseases. *Molecular aspects of medicine*. 26 : 33-65.
- Nathan, C. (1992). Nitric oxide as a secretory product of mammalian cells. *FASEB Journal*. 6(12): 3051-3064.
- Newman, D. J., and Cragg, G. M. (2007). Natural products as sources of new drugs over the last 25 years. *Journal of Natural Products*. 70(3): 461-477.
- Nirmala, C., and Puvanakrishnan, R. (1996). Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. *Biochemical Pharmacology*. 51(1): 47-51.
- Nowakowska, Z. (2007). A review of anti-infective and anti-inflammatory chalcones. *European Journal of Medicinal Chemistry*. 42(2): 125-137.
- Orlikova, B., Tasdemir, D., Golais, F., Dicato, M., and Diederich, M. (2011). The aromatic ketone 4'-hydroxychalcone inhibits TNF- α -induced NF- κ B activation via proteasome inhibition. *Biochemical Pharmacology*. 82(6): 620-631.
- Pari, L., and Murugan, P. (2004). Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. *Pharmacological Research*. 49(5): 481-486.
- Patrick, G. L. 2013. Chapter 12 – Finding a Lead Compound. *An Introduction to Medicinal Chemistry*. Pp. 199-200. Oxford : Oxford University Press.
- Patrick, G. L. 2013. Chapter 13 – Drug Optimization : Strategies in Drug Design. *An Introduction to Medicinal Chemistry*. Pp. 239. Oxford : Oxford University Press.
- Pinto, Diana C. G. A., Silva, Artur M. S., Lévai, A., Cavaleiro, José A. S., Patonay, T., and Elguero, J. (2000). Synthesis of 3-Benzoyl-4-styryl-2-pyrazolines and Their Oxidation to the Corresponding Pyrazoles. *European Journal of Organic Chemistry*. 2000(14): 2593-2599.
- Popa, C., Netea, M. G., van Riel, P. L., van der Meer, J. W., and Stalenhoef, A. F. (2007). The role of TNF-alpha in chronic inflammatory conditions,

- intermediary metabolism, and cardiovascular risk. *Journal of Lipid Research*. 48(4): 751-762.
- Prasad, Y. R., Rao, A. L., and Rambabu, R. (2008). Synthesis and Antimicrobial Activity of Some Chalcone Derivatives. *E-Journal of Chemistry*. 5(3): 461-466.
- Prasad, S., Tyagi, A.K., and Aggarwal, B.B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin : the golden pigment from golden spice. *Cancer Research and Treatment : Official Journal of Korean Cancer Association*. 46(1): 2-18
- Priyadarshini, K., and Keerti Aparajitha, U. (2012). *Medicinal Chemistry*. 2 ; 139-141.
- Puratchikody, A., and Doble, M. (2007). Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles. *Bioorganic & Medicinal Chemistry*. 15(2): 1083-1090.
- Qiu, X., Du, Y., Lou, B., Zuo, Y., Shao, W., Huo, Y., and Bu, X. (2011). Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-kappaB signaling pathway. *Journal of Medicinal Chemistry*. 53(23): 8260-8273.
- Ravindran, J., Prasad, S., and Aggarwal, B. B. (2009). Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? *AAPS Journal*. 11(3): 495-510.
- Ridnour, L. A., Thomas, D. D., Switzer, C., Flores-Santana, W., Isenberg, J. S., Ambs, S., Roberts, D. D., and Wink, D. A. (2008). Molecular mechanisms for discrete nitric oxide levels in cancer. *Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society*. 19 : 73-76.
- Rojas, J., Dominguez, J. N., Charris, J. E., Lobo, G., Paya, M., and Ferrandiz, M. L. (2002). Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. *European Journal of Medicinal Chemistry*. 37(8): 699-705.
- Sardjiman, S. S., Reksodiprodjo, M. S., Hakim, L., van der Goot, H., and Timmerman, H. (1997). 1,5-Diphenyl-1,4-pentadiene-3-ones and cyclic analogues as antioxidative agents. Synthesis and structure-activity relationship. *European Journal of Medicinal Chemistry*. 32: 625.
- Schieven, G. L. (2005). The biology of p38 kinase: a central role in inflammation. *Current Topics in Medicinal Chemistry*. 5(10): 921-928.
- Schroder, K., Hertzog, P. J., Ravasi, T., and Hume, D. A. (2004). Interferon-gamma: an overview of signals, mechanisms and functions. *Journal of Leukocyte Biology*. 75(2): 163-189.
- Sharma, O. P. (1976). Antioxidant activity of curcumin and related compounds. *Biochemical Pharmacology*. 25(15): 1811-1812.

- Shen, W., Li, Y., Zhu, J., Schwendener, R., and Huard, J. (2008). Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. *Journal of Cellular Physiology*. 214(2): 405-412.
- Shim, J. S., Kim, D. H., Jung, H. J., Kim, J. H., Lim, D., Lee, S. K., and Kwon, H. J. (2002). Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. *Bioorganic & Medicinal Chemistry*. 10(9): 2987-2992.
- Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., and Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Medica*. 64(4): 353-356.
- Sikora, E., Bielak-Zmijewska, A., Magalska, A., Piwocka, K., Mosieniak, G., Kalinowska, M., and Bujnicki, J. M. (2006). Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. *Molecular Cancer Therapeutics*. 5(4): 927-934.
- Simoni, D., Rizzi, M., Rondanin, R., Baruchello, R., Marchetti, P., Invidiata, F. P., and D'Alessandro, N. (2008). Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells. *Bioorganic & Medicinal Chemistry Letters*. 18(2): 845-849.
- Singh, S., and Aggarwal, B. B. (1995). Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). *Journal of Biology Chemistry*. 270(42): 24995-25000.
- Siwak, D. R., Shishodia, S., Aggarwal, B. B., and Kurzrock, R. (2005). Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. *Cancer*. 104(4): 879-890.
- Srivastava, R., Dikshit, M., Srimal, R. C., and Dhawan, B. N. (1985). Anti-thrombotic effect of curcumin. *Thrombosis Research*. 40(3): 413-417.
- Sun, L., and Ye, R. D. (2012). Role of G protein-coupled receptors in inflammation. *Acta Pharmacologica Sinica*. 33(3): 342-350.
- Surh, Y. J., Chun, K. S., Cha, H. H., Han, S. S., Keum, Y. S., Park, K. K., and Lee, S. S. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. *Mutation Research*. 480-481 : 243-268.

The immune system. N.d. Retrieved 3rd May 2011 from <http://www.uic.edu/classes/bios/bios100/lecturef04am/lect23.htm>

- Tomar, V., Bhattacharjee, G., Kamaluddin, Rajakumar, S., Srivastava, K., and Puri, S. K. (2010). Synthesis of new chalcone derivatives containing acridinyl moiety with potential antimalarial activity. *European Journal of Medicinal Chemistry*. 45(2): 745-751.
- Tong, Q. S., Zheng, L. D., Lu, P., Jiang, F. C., Chen, F. M., Zeng, F. Q., and Dong, J. H. (2006). Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. *Anticancer Drugs*. 17(3): 279-287.
- Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., and Kopple, K.D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. *Journal of medicinal chemistry*. 45 : 2615-2623.
- Venkatesan, N. (1998). Curcumin attenuation of acute adriamycin myocardial toxicity in rats. *British Journal of Pharmacology*. 124(3): 425-427.
- Venkatesan, N., Punithavathi, D., and Arumugam, V. (2000). Curcumin prevents adriamycin nephrotoxicity in rats. *British Journal of Pharmacology*. 129(2): 231-234.
- Vogel, S., Barbic, M., Jurgenliemk, G., and Heilmann, J. (2010). Synthesis, cytotoxicity, anti-oxidative and anti-inflammatory activity of chalcones and influence of A-ring modifications on the pharmacological effect. *European Journal of Medicinal Chemistry*. 45(6): 2206-2213.
- Vogel, S., Ohmayer, S., Brunner, G., and Heilmann, J. (2008). Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity. *Bioorganic & Medicinal Chemistry*. 16(8): 4286-4293.
- Vonkeman, H., Meek, I., and van de Laar, M. (2010). Risk management of risk management: Combining proton pump inhibitors with low dose aspirin. *Drug Healthc Patient Saf*. 2: 191-204.
- Vyas, A., Dandawate, P., Padhye, S., Ahmad, A., and Sarkar, F. (2013). Perspectives on new synthetic curcumin analogs and their potential anticancer properties. *Current Pharmaceutical Design*. 19(11): 2047-2069.
- Waetzig, V., Czeloth, K., Hidding, U., Mielke, K., Kanzow, M., Brecht, S., and Hanisch, U. K. (2005). c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. *Glia*. 50(3): 235-246.
- Wang, L., Tu, Y. C., Lian, T. W., Hung, J. T., Yen, J. H., and Wu, M. J. (2006). Distinctive antioxidant and antiinflammatory effects of flavonols. *Journal of Agricultural and Food Chemistry*. 54(26): 9798-9804.
- Weber, W. M., Hunsaker, L. A., Roybal, C. N., Bobrovnikova-Marjon, E. V., Abcouwer, S. F., Royer, R. E., and Vander Jagt, D. L. (2006). Activation of NFkappaB is inhibited by curcumin and related enones. *Bioorganic & Medicinal Chemistry*. 14(7): 2450-2461.

- Won, S. J., Liu, C. T., Tsao, L. T., Weng, J. R., Ko, H. H., Wang, J. P., and Lin, C. N. (2005). Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. *European Journal of Medicinal Chemistry*. 40(1): 103-112.
- Woo, J. H., Kim, Y. H., Choi, Y. J., Kim, D. G., Lee, K. S., Bae, J. H., and Kwon, T. K. (2003). Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. *Carcinogenesis*. 24(7): 1199-1208.
- Yamamoto, Y., and Gaynor, R. B. (2001). Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. *Journal of Clinical Investigation*. 107(2): 135-142.
- Yang, H. M., Shin, H. R., Cho, S. H., Bang, S. C., Song, G. Y., Ju, J. H., and Jung, S. H. (2007). Structural requirement of chalcones for the inhibitory activity of interleukin-5. *Bioorganic & Medicinal Chemistry*. 15(1): 104-111.
- Zandi, E., and Karin, M. (1999). Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex. *Molecular and Cellular Biology*. 19(7): 4547-4551.

LIST OF PUBLICATIONS

1. Sze Wei Leong, Siti Munirah Mohd Faudzi, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam KokWai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. Synthesis and SAR study of curcuminoid analogues as new anti-inflammatory agents. *Molecules*. – **Published**
2. Siti Munirah Mohd Faudzi, Leong Sze Wei, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam KokWai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. Synthesis, biological evaluation, QSAR studies of diarylpentanoid analogues as potential nitric oxide inhibitors. *Medicinal Chemistry Communication*. - **Published**
3. Leong Sze Wei, Siti Munirah Mohd Faudzi, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam KokWai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. Antioxidant and anti-inflammatory properties of asymmetrical diarylpentanoid derivatives. *Medicinal Chemistry Research*. - **Submitted**
4. Siti Munirah Mohd Faudzi, Leong Sze Wei, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam Kok Wai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. Synthesis and anti-inflammatory evaluation of pyrazoline derivatives of diarylpentenedione analogues. *Medicinal Chemistry Research*. - **Under review**
5. Leong Sze Wei, Siti Munirah Mohd Faudzi, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam KokWai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. Acetyl- and butyrylcholinesterase inhibitory effects of diarylpentanoid derivatives. *Bioorganic & Medicinal Chemistry Letters*. – **Under review**

LIST OF CONFERENCES ATTENDED

1. Siti Munirah Mohd Faudzi, Faridah Abas, Lam Kok Wai, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. "Synthesis and Anti-tyrosinase activity of diarylpentanoic acid analogues". Poster presentation at 17th Malaysian Chemical Congress (17 MCC), Putra World Trade Centre, Kuala Lumpur, 15th-17th October 2012.
2. Siti Munirah Mohd Faudzi, Leong Sze Wei, Faridah Abas, Lam Kok Wai, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. "Design, synthesis and biological evaluation of diarylpentanoic acid derivatives as new anti-inflammation agents". Poster presentation at 2nd Junior ICCEOCA (ACP), Universiti Malaya, Kuala Lumpur, 8th-11th December 2012.
3. Siti Munirah Mohd Faudzi, Leong Sze Wei, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam Kok Wai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. "Design, synthesis, biological evaluation, and SAR studies of diarylpentanoic acid analogues as potential anti-inflammation agents". Oral presentation at International Conference on Natural Products (ICNP) 2014, Palm Garden Hotel, IOI Resort Putrajaya, 18th-19th March 2014.
4. Siti Munirah Mohd Faudzi, Leong Sze Wei, Faridah Abas, Mohd Fadhlizil Fasihi Mohd Aluwi, Kamal Rullah, Lam Kok Wai, Mohd Nazri Abdul Bahari, Syahida Ahmad, Chau Ling Tham, Khozirah Shaari, Nordin H. Lajis. "Design, synthesis and biological evaluation of diarylpentanoic acid analogues as potential NO inhibitor". Oral presentation at Medan International Conference on Advanced Pharmaceuticals Sciences (MICAPS) 2014, Garuda Plaza Hotel, Medan, Indonesia, 3rd-4th November 2014.